BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 30700046)

  • 21. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of MDA-MB-231 breast cancer cell proliferation and tumor growth by apigenin through induction of G2/M arrest and histone H3 acetylation-mediated p21
    Tseng TH; Chien MH; Lin WL; Wen YC; Chow JM; Chen CK; Kuo TC; Lee WJ
    Environ Toxicol; 2017 Feb; 32(2):434-444. PubMed ID: 26872304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxico-pharmacological evaluations of the small-molecule LQFM166: Inducer of apoptosis and MDM2 antagonist.
    Dos Santos TRM; Garcia da Silva AC; de Carvalho FS; Sanz G; Vaz BG; Lião LM; Menegatti R; Valadares MC
    Chem Biol Interact; 2018 Sep; 293():20-27. PubMed ID: 30057354
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
    Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
    BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
    Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
    J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic Combination of Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid and Natural Flavonoid Curcumin Exhibits Anticancer and Antibacterial Activity.
    Altundağ EM; Toprak K; Şanlıtürk G; Güran M; Özbilenler C; Kerküklü NR; Yılmaz AM; Yalçın AS
    Anticancer Agents Med Chem; 2021; 21(10):1301-1308. PubMed ID: 33023457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Green tea polyphenols causes cell cycle arrest and apoptosis in prostate cancer cells by suppressing class I histone deacetylases.
    Thakur VS; Gupta K; Gupta S
    Carcinogenesis; 2012 Feb; 33(2):377-84. PubMed ID: 22114073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of cell cycle by MDM2 in prostate cancer cells through Aurora Kinase-B and p21WAF1
    Kanagasabai T; Venkatesan T; Natarajan U; Alobid S; Alhazzani K; Algahtani M; Rathinavelu A
    Cell Signal; 2020 Feb; 66():109435. PubMed ID: 31706019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway.
    Singh SK; Banerjee S; Acosta EP; Lillard JW; Singh R
    Oncotarget; 2017 Mar; 8(10):17216-17228. PubMed ID: 28212547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
    Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.
    Zhou Z; Zalutsky MR; Chitneni SK
    Mol Pharm; 2021 Oct; 18(10):3871-3881. PubMed ID: 34523337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticancer effects of the HDAC inhibitor, 3β,6β‑dihydroxyurs‑12‑en‑27‑oic acid, in MCF‑7 breast cancer cells via the inhibition of Akt/mTOR pathways.
    Lim JS; Kyung SY; Jeon Y; Kim IS; Kwak JH; Kim HS
    Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36633143
    [No Abstract]   [Full Text] [Related]  

  • 37. Vorinostat enhances protein stability of p27 and p21 through negative regulation of Skp2 and Cks1 in human breast cancer cells.
    Uehara N; Yoshizawa K; Tsubura A
    Oncol Rep; 2012 Jul; 28(1):105-10. PubMed ID: 22484732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanoencapsulation of MDM2 Inhibitor RG7388 and Class-I HDAC Inhibitor Entinostat Enhances their Therapeutic Potential Through Synergistic Antitumor Effects and Reduction of Systemic Toxicity.
    Abed A; Greene MK; Alsa'd AA; Lees A; Hindley A; Longley DB; McDade SS; Scott CJ
    Mol Pharm; 2024 Mar; 21(3):1246-1255. PubMed ID: 38334409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
    Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
    Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells.
    Reddy ND; Shoja MH; Biswas S; Nayak PG; Kumar N; Rao CM
    Chem Biol Interact; 2016 Jun; 253():112-24. PubMed ID: 27163855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.